Akcea Therapeutics Stock Price, News & Analysis (NASDAQ:AKCA)

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Akcea Therapeutics Inc (NASDAQ:AKCA) announced its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.40) EPS for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.02. The company had revenue of $26.62 million for the quarter, compared to analyst estimates of $25.78 million. Akcea Therapeutics had a negative net margin of 65.62% and a negative return on equity of 43.87%. The firm's quarterly revenue was up 45.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.85) EPS. View Akcea Therapeutics' Earnings History.

Akcea Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Akcea Therapeutics.

4 analysts have issued 12 month price objectives for Akcea Therapeutics' shares. Their predictions range from $24.00 to $45.00. On average, they expect Akcea Therapeutics' share price to reach $36.00 in the next twelve months. This suggests a possible upside of 98.2% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.

Media coverage about AKCA stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Akcea Therapeutics earned a news sentiment score of 1.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Akcea Therapeutics.

Akcea Therapeutics saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 5,160,000 shares, a decrease of 14.3% from the August 30th total of 6,020,000 shares. Based on an average daily volume of 263,500 shares, the short-interest ratio is currently 19.6 days. Approximately 35.0% of the company's shares are sold short. View Akcea Therapeutics' Current Options Chain.

Some companies that are related to Akcea Therapeutics include Teva Pharmaceutical Industries (TEVA), Perrigo (PRGO), SAGE Therapeutics (SAGE), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), Beigene (BGNE), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), The Medicines (MDCO), GW Pharmaceuticals PLC- (GWPH) and Blueprint Medicines (BPMC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Achaogen (AKAO), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC), Apollo Global Management (APO) and Ciena (CIEN).

(AKCA) raised $125 million in an IPO on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKCA stock can currently be purchased for approximately $18.16.

Akcea Therapeutics has a market capitalization of $1.69 billion and generates $64.87 million in revenue each year. The company earns $-225,820,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.View Additional Information About Akcea Therapeutics.

The official website for Akcea Therapeutics is http://www.akceatx.com/.

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]